EP4104851A1 - Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus - Google Patents
Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus Download PDFInfo
- Publication number
- EP4104851A1 EP4104851A1 EP20951308.4A EP20951308A EP4104851A1 EP 4104851 A1 EP4104851 A1 EP 4104851A1 EP 20951308 A EP20951308 A EP 20951308A EP 4104851 A1 EP4104851 A1 EP 4104851A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- coronavirus
- epazote
- composition
- oregano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 22
- 239000004094 surface-active agent Substances 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 239000000419 plant extract Substances 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- 229920001436 collagen Polymers 0.000 claims abstract description 25
- 244000281762 Chenopodium ambrosioides Species 0.000 claims abstract description 17
- 240000007673 Origanum vulgare Species 0.000 claims abstract description 17
- 239000003755 preservative agent Substances 0.000 claims abstract description 17
- 240000003718 Petiveria alliacea Species 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 235000013628 Lantana involucrata Nutrition 0.000 claims abstract description 14
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims abstract description 14
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 9
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 9
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 238000005238 degreasing Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 240000007232 Illicium verum Species 0.000 claims abstract description 6
- 235000008227 Illicium verum Nutrition 0.000 claims abstract description 6
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 claims abstract description 3
- 235000010677 Origanum vulgare Nutrition 0.000 claims abstract description 3
- 235000006754 Taraxacum officinale Nutrition 0.000 claims abstract description 3
- 239000006286 aqueous extract Substances 0.000 claims abstract description 3
- 235000006645 dysphania ambrosioides Nutrition 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 14
- 244000269722 Thea sinensis Species 0.000 claims description 11
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 9
- 229940102223 injectable solution Drugs 0.000 claims description 9
- 235000010241 potassium sorbate Nutrition 0.000 claims description 9
- 239000004302 potassium sorbate Substances 0.000 claims description 9
- 229940069338 potassium sorbate Drugs 0.000 claims description 9
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 9
- 235000010234 sodium benzoate Nutrition 0.000 claims description 9
- 239000004299 sodium benzoate Substances 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229940067866 dandelion extract Drugs 0.000 claims description 8
- 235000020691 dandelion extract Nutrition 0.000 claims description 8
- 229940045955 star anise extract Drugs 0.000 claims description 8
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 238000007918 intramuscular administration Methods 0.000 claims description 7
- 239000007903 gelatin capsule Substances 0.000 claims description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 238000007689 inspection Methods 0.000 claims description 4
- 229960004194 lidocaine Drugs 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 6
- 230000008569 process Effects 0.000 description 27
- 239000007788 liquid Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 241000700605 Viruses Species 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 9
- 239000012467 final product Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 238000007789 sealing Methods 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical group CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000003631 expected effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 238000010977 unit operation Methods 0.000 description 2
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000036002 Rash generalised Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000027499 body ache Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013527 degreasing agent Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
Definitions
- the present invention relates to antimicrobial compositions capable of inhibiting the transmission of a virus, in particular the coronavirus, and its treatment, based on a surfactant with degreasing properties, combined with natural plant extracts, as well the method of obtaining said composition.
- the coronavirus is one of the viruses that is wreaking the most havoc across the world population.
- a trial with a completely natural formula can reduce the risks to a minimum.
- Patent CA2569080A from 2006 refers to the field of coronavirus and molecules for its prevention.
- Patent CN100500162C requested by TOAGOSEI CO LTD in 2003 provides effective management of the coronavirus and can be converted into the various antiviral agent of many cleaning products, it contains a silver ion carrier antiviral agent that may inactivate the virus, but selected of chemical compound.
- Patent CN105687226A from 2016 deals with a preparation to inhibit coronavirus infections having Astragalus as the active ingredient.
- Patent JP2003384125A deals with an aerosol disinfectant preventing infectious disease, either by air or by direct treatment into the hands, its active ingredient is hinokitiol, aloe vera, green tea, albomarginata and houttuynia cordata, it is sprayed and said to prevent the spread of infection.
- the mortality rate of infected people up to 40 years old is 0.2%, but among those between 70 and 79 years old it increases up to 8%, while from 80 years old and the number increases up to 14.8%.
- the present invention aims to develop a pharmaceutical formulation obtained by combining the powdered extract obtained from aqueous extracts of different plants and a surfactant with degreasing properties as active ingredients, without side effects from its intake.
- the present invention has as its object the formulation of different pharmaceutical dosage forms such as capsules, tea, drinkable ampoules, and injectable solution ampoules that comprise non-hydrolyzed collagen as a surfactant, (soap), powdered extracts of Dandelion (Taraxacum officinale), Anamu (Petiveria Alliacea), Epazote (Dysphania ambrosioides), Oregano, (Origanum vulgare), Star Anise, (Illicium verum), together with preservatives for the treatment of patients suffering from coronavirus, surprisingly obtaining a notable improvement 24 hours after starting treatment, and it has been possible to verify an integral and significant improvement at 48 hours after applying the administration regimen.
- a surfactant such as capsules, tea, drinkable ampoules, and injectable solution ampoules that comprise non-hydrolyzed collagen as a surfactant, (soap), powdered extracts of Dandelion (Taraxacum officinal
- Surfactants have antibacterial properties that is why they can eliminate microorganisms, due to their cleaning power.
- collagen is the most abundant protein in our body, the main component of the tissues that make up various parts of the body, including tendons, ligaments, gums, teeth, skin and muscles.
- the procedure for preparing these capsules includes several stages:
- the capsules thus obtained according to the described process have a storage stability at ambient conditions of 2 years.
- capsules obtained according to example 1 patients diagnosed with coronavirus shall be prescribe for 7 days with a dosage of three capsules per day with a composition of ingredients as follows: Non-hydrolyzed collagen 25% Dandelion extract 20% Anamu extract 10% Epazote extract 15% Oregano extract 19.5% Star anise extract 10% Sodium benzoate 0.25% Potassium sorbate 0.25%
- the homogeneous powder obtained according to steps 1 to 5 previously described in the procedure for obtaining the capsules is now packed in bags or sacks of porous paper, silk or nylon, similar to those used in tea bags from which it is prepared. an infusion with hot water useful in the treatment of coronavirus.
- the bags obtained according to the described process have a storage stability at ambient conditions of 2 years.
- the procedure for the preparation of drinkable ampoules consists of the following steps:
- the ampoules of injectable solution thus obtained according to the described process have an ambient storage stability of 2 years.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present invention relates to antimicrobial compositions capable of inhibiting the transmission of a virus, in particular the coronavirus, and its treatment, based on a surfactant with degreasing properties, combined with natural plant extracts, as well the method of obtaining said composition.
- The coronavirus is one of the viruses that is wreaking the most havoc across the world population.
- Much is said about it, but until now we have not achieved a medicine or a vaccine capable of preventing and controlling it.
- Every day new expectations of studies appear, but none that we can affirm with property this is what stops it.
- The damage caused to both humanity and the economy is incalculable.
- But we cannot drink a shampoo or a cleansing gel due to its harmful effects on health, and its consequences, but that would be a solution.
- One of the great inconveniences that arise is that there are times when the coronavirus does not present any symptoms, which is the main danger since a large group of people can be infected without even knowing it.
- Given the death rate from this disease, saving time is a must.
- A trial with a completely natural formula can reduce the risks to a minimum.
- Patent
CA2569080A from 2006 refers to the field of coronavirus and molecules for its prevention. - Patent
CN100500162C requested by TOAGOSEI CO LTD in 2003 provides effective management of the coronavirus and can be converted into the various antiviral agent of many cleaning products, it contains a silver ion carrier antiviral agent that may inactivate the virus, but selected of chemical compound. PatentCN105687226A from 2016 deals with a preparation to inhibit coronavirus infections having Astragalus as the active ingredient. - Patent
JP2003384125A from 2003 - Tests pose complex ethical situations, but for these unusual situations, we will have to look for unusual solutions as well.
- It is known that the people with the lowest risk of death or developing a severe form of the disease are young people without pre-existing health conditions.
- Older people are the most at risk. The mortality rate increases exponentially from the age of 65, approximately.
- In China, for example, the mortality rate of infected people up to 40 years old is 0.2%, but among those between 70 and 79 years old it increases up to 8%, while from 80 years old and the number increases up to 14.8%.
- Fortunately, so far, no children have died from coronavirus.
- Evidently, there are children who are also infected with the virus, but they do not get sick, or only show slight symptoms.
- Much has been said about the causes, but nothing that gives an answer to it yet.
- The present invention aims to develop a pharmaceutical formulation obtained by combining the powdered extract obtained from aqueous extracts of different plants and a surfactant with degreasing properties as active ingredients, without side effects from its intake.
- More particularly, the present invention has as its object the formulation of different pharmaceutical dosage forms such as capsules, tea, drinkable ampoules, and injectable solution ampoules that comprise non-hydrolyzed collagen as a surfactant, (soap), powdered extracts of Dandelion (Taraxacum officinale), Anamu (Petiveria Alliacea), Epazote (Dysphania ambrosioides), Oregano, (Origanum vulgare), Star Anise, (Illicium verum), together with preservatives for the treatment of patients suffering from coronavirus, surprisingly obtaining a notable improvement 24 hours after starting treatment, and it has been possible to verify an integral and significant improvement at 48 hours after applying the administration regimen.
- Currently there is no pharmaceutical formula that contains a surfactant with degreasing properties as a base and that can be ingested at the same time.
- We have achieved a formula that contains a surfactant with degreasing properties and can be taken without side effects, with the benefit of preventing the virus from surviving. We are facing a great solution for the world.
- So far, the only thing that has been shown to stop and delay its spread is soap, because coronaviruses are wrapped in a lipid layer that soap inhibits.
- It is known that washing body parts, Ex. washing hands and hard surfaces, countertops and sinks can significantly decrease the population of microorganisms including pathogens. Coronaviruses have a lipid membrane that gives the particle relatively low stability, especially when compared to the naked particle of the common cold virus. That makes it relatively easy to remove them from your hands using soapy solutions.
- Therefore, protection seems simple, social distance and use of soap.
- Surfactants have antibacterial properties that is why they can eliminate microorganisms, due to their cleaning power.
- What we can see is that there is a relationship with the production and decrease of collagen. When collagen is at its maximum production, the incidence is very slight, but it increases as well as its production decreases, which is why it attacks the elderly more strongly since they do not produce collagen at that age.
- We know that collagen is the most abundant protein in our body, the main component of the tissues that make up various parts of the body, including tendons, ligaments, gums, teeth, skin and muscles.
- As a result of the tests carried out, we were able to verify that when using plant extracts with non-hydrolyzed collagen for their surfactants and degreasing power, (as detailed in patent P-
2019-0173 filed in 2019 by Rosa Maria Portillo - Which comes to solve the problem that we are experiencing at the moment, in this case a product of covid-19, since this would be the only pharmaceutical formulation that contains a degreaser in its formulation and that can be ingested without side effects, either in a tea for the elderly, one capsule, one drinkable ampoule, one injectable ampoule.
- The fundamental ingredients that are combined in the composition, as well as the functions that they fulfill within the composition are the following:
- Non-hydrolyzed collagen:
It is a natural active ingredient and a key protein in the human body, not hydrolyzed it is a surfactant with degreasing and cleansing properties, and as it is not hydrolyzed the molecule is larger which will make the process of crossing the intestinal barrier slower, with which can inhibit the virus in the intestinal tract. - Dandelion:
It contains high levels of the antioxidant beta-carotene, which provides strong protection against cell damage and oxidative stress, prevents bleeding in the liver, and contributes to blood cleansing. It protects liver tissue, and has diuretic properties widely used in kidney problems. - Anamu:
It is analgesic and anti-inflammatory in various skin conditions. - Epazote
- It is a natural antiparasitic, has calming and relaxing properties.
- It is used to treat stomach problems such as diarrhea, vomiting, and stomach pain. Helps treat flu and cough.
- Oregano:
With properties for conditions of the respiratory system with congestion, due to its anti-inflammatory, analgesic and antiseptic effect and it has an antimicrobial effect. - Star anise:
Used for spasms of the stomach and gallbladder. With antibacterial and fungicidal active ingredients, used to treat flu, bronchitis, cough and asthma. - Sodium benzoate:
- preservative
- Potassium sorbate:
- Preservative.
- The qualitative and quantitative composition by weight of the active ingredients, solvents and preservatives proposed in this formulation, as well as their function within the composition, is as follows:
Non-hydrolyzed collagen 1%-35% Surfactants Dandelion extract 5%-30% Active ingredient Epazote extract 3%-20% Active ingredient Oregano extract 3%-20% Active ingredient Star anise extract 5%- 25% Active ingredient Sodium benzoate 1%-15% Preservative Potassium sorbate extract 0.25% Preservative Treated water 15%-19.5% Solvent - The procedure for preparing these capsules includes several stages:
- 1. In the first stage of the process, the different raw materials are prepared, which entails the inspection, classification, and approval of the raw material to be used in the production of the final product, which will reach a final product in powder form. which is filled into hard gelatin capsules.
- 2. After the raw materials have been approved in the raw material reception area, they go to the pre-production area where they are prepared for entry into the production area. It is in this area where the shell is removed from those raw materials that require it, as well as the seeds, are cleaned and rinsed with treated water from the treatment plant.
- 3. When the raw materials leave this area, they enter the production area where they enter a stainless-steel mixer with temperature control, which is fed with steam from a Pyro-tubular boiler, which allows the temperature to be increased. in the same. In this mixer we add all the raw materials of the formula except for the non-hydrolyzed collagen and the preservatives, because these must be added in the final stage of the process at a temperature of 30°C to 40°C to avoid their degradation by temperature and then they are damage the product over time.
In this mixer, the different raw materials, all mixed within it, are subjected to a temperature of 96°C (205°F), followed by periods of agitation every 5 minutes, with the aim that at that temperature the water can absorb the properties and nutrients from each of the raw materials present in the mixer, this will allow us to obtain a well-charged liquid, rich in all the properties from the herbs, fruits and raw materials that were subjected in this part of the production process. - 4. The resulting liquid that comes out of the mixer now goes to another piece of equipment called a pressure filter. It is in this equipment that even the smallest solid particle that may be mixed with the liquid extract is separated. The objective in this part of the process is to obtain a liquid free of solid particles. At this stage we will take the opportunity to add the collagen and the Preservatives.
- 5. The filtered liquid passes to a Spray Dryer ADL 311 type spray dryer or spray dryer. At this stage of the process, what is achieved is that the liquid from the pressure filter turns into powder. The feed of the concentrated and filtered liquid is fed by means of a peristaltic pump with a silicone hose, this spray equipment has a temperature system, spray system at the tip of the outlet nozzle, blower, heater, suction filter and exhaust filter, through which it performs the drying and subsequent spraying of the liquid, converting it into powder.
- 6. The powder obtained in the Pulverization equipment now goes to a NJP 1200D Encapsulating Machine, which is an automatic machine that allows the powdered product to be encapsulated in Gelatin Capsules, which can be #0 Gelatin Capsules, for example, in #0 Red/Black hard gelatin capsules from ACG Associated Capsules Pvt Ltd.
- 7. Once the product is encapsulated, these capsules will now go to a piece of equipment called the SP-G100 Capsule Packing Machine. The objective to be achieved in this equipment is to place the capsules in the final package, which will serve as a vehicle to make get the product to the final consumer.
- The capsules thus obtained according to the described process have a storage stability at ambient conditions of 2 years.
- With the capsules obtained according to example 1, patients diagnosed with coronavirus shall be prescribe for 7 days with a dosage of three capsules per day with a composition of ingredients as follows:
Non-hydrolyzed collagen 25% Dandelion extract 20% Anamu extract 10% Epazote extract 15% Oregano extract 19.5% Star anise extract 10% Sodium benzoate 0.25% Potassium sorbate 0.25% - The homogeneous powder obtained according to steps 1 to 5 previously described in the procedure for obtaining the capsules is now packed in bags or sacks of porous paper, silk or nylon, similar to those used in tea bags from which it is prepared. an infusion with hot water useful in the treatment of coronavirus. The bags obtained according to the described process have a storage stability at ambient conditions of 2 years.
- Based on my personal experience:
I was the first model for the study, the symptoms began, I felt a dry cough, shortness of breath, diarrhea, body aches, tiredness. the rash all over my belly and back I knew I was infected, I took the test, it was positive. I am a high-risk patient, 60 years old, high blood sugar, high blood pressure, too many factors against me. I prepared the formula mentioned below, I refrained from taking any medication, only my formula, surprisingly the symptoms had begun to disappear within hours, the pain went away, I began to breathe normally, the diarrhea disappeared, the hardest thing was the rash on the body, which was completely eliminated within two days of taking the formula. - I only had to drink for 7 days, 2 cups a day, of the following composition of ingredients:
Non-hydrolyzed collagen 30% Dandelion 15% Anamu 15% Epazote 17% Oregano 15% Star anise extract 7.50% Sodium benzoate 0.25% Potassium sorbate 0.25% - The procedure for the preparation of drinkable ampoules consists of the following steps:
- 1. In the first stage of the process, the different raw materials are received at the plant, which will go through an inspection, classification, and approval process to be used in the production of our final product, which will be drinkable ampoules.
- 2. After the raw materials have been approved in the raw material reception area, they go to the pre-production area where they are prepared for entry into the production area. It is in this area where the shell is removed from those materials. raw materials that require it, as well as the seeds, are cleaned and rinsed with treated water from the treatment plant.
- 3. When the raw materials leave this area, they enter the production area where the first equipment or unit operation they enter is a stainless-steel mixer with temperature control, which is fed with steam, which allows to achieve the increase of the temperature in it. In this mixer we add all the raw materials of our formula, except the non-hydrolyzed collagen and the preservatives, because these must be added at a temperature of 30°C to 40°C to avoid their degradation due to high temperatures and that later they do not can have the expected effect on the final product.
- 4. In this mixer, the different raw materials, all mixed within it, are subjected to a temperature of 96°C (205°F), followed by periods of agitation every 5 minutes, with the aim that at that temperature the water can absorb the properties and nutrients of each of the raw materials present in the mixer, this will allow us to obtain a well-charged liquid, rich in all the properties from the herbs, fruits and raw materials that were subjected in this part of the production process.
- 5. The resulting liquid that comes out of the mixer now goes to another piece of equipment called a pressure filter. It is in this equipment that even the smallest solid particle that may be mixed with the liquid extract is separated. The objective in this part of the process is to obtain a liquid free of solid particles. At this stage we will take the opportunity to add the non-hydrolyzed collagen and the preservatives.
- 6. The container chosen to store the final product is the container: Special Ampoules for Drinkable Solutions.
- 7. These containers are subjected to an automatic washing process in a machine that provides a pressurized water jet, this water is totally purified.
- 8. Once these containers leave the washing process, they enter a sterilization machine or dryer that will be in charge of sterilizing and drying the containers through the action of high temperatures.
- 9. Upon leaving the sterilization or drying machine, these containers enter an SCT Pharma oven, where the dehydrogenation process will be carried out, which is nothing more than the process that will allow us to reduce the total or almost total endotoxins. Bacterial (Pyrogens), in other words what we are looking for is to obtain blisters free of all microorganisms and undesirable pathogenic substances, we achieve this through processes that use high temperatures, such as those that have been previously exposed.
- 10. The resulting solution obtained in step 5. From the filter. You will now move on to a piece of equipment called a vial filling and sealing machine. The objective in this step is to dose the filtered solution as quickly as possible into the drinkable ampoules, taking care not to wet the neck of the ampoules. This machine will subsequently be responsible for sealing the valves, since it has a sealing system for this type of ampoules.
- 11. The next stage is the stage called labeling, stage in which the label is placed on the product including elementary information such as: Lot number, Dosage, Manufacturing Date, Expiration Date, etc.
- 12. In the final stage of our process, we find the storage of our finished product, under favorable conditions of temperature and humidity, characteristic of this type of product. The drinkable ampoules thus obtained according to the process described have an ambient storage stability of 2 years.
- Patients with coronavirus must undergo treatment for a period of 7 days and with a dosage of 3 drinkable ampoules per day, with a composition of ingredients per ampule of:
Properly treated water 19.5% Non-hydrolyzed collagen 35% Dandelion Extract 10% Anamu extract 8% Epazote 12% Oregano 10% Star anise 5% Sodium benzoate 0.25% Potassium Sorbate 0.25% - The procedure for the preparation of an intramuscular injectable solution consists of the following steps:
- 1. On the first stage of the process, the different raw materials are received at the plant, which will go through an inspection, classification, and approval process to be used in the production of our final product, which will be an intramuscular injectable solution.
- 2. After the raw materials have been approved in the raw material reception area, they go to the pre-production area where they are prepared for entry into the production area. It is in this area where the shell is removed from those materials. raw materials that require it, as well as the seeds, are cleaned and rinsed with treated water from the treatment plant.
- 3. When the raw materials leave this area, they enter the production area where the first equipment or unit operation they enter is a stainless-steel mixer with temperature control, which is fed with steam, which allows to achieve the increase of the temperature in it. In this mixer we add all the raw materials of our formula, except for the non-hydrolyzed collagen, the lidocaine, the preservative and the ascorbic acid, because these must be added at a temperature of 30°C to 40°C to avoid their degradation by high temperatures and then cannot have the expected effect on the final product.
- 4. The different raw materials are placed in this mixer, all mixed within it, they are subjected to a temperature of 96°C (205°F), followed by periods of agitation every 5 minutes, with the aim that at that temperature the water can absorb the properties and nutrients of each of the raw materials present in the mixer, this will allow us to obtain a well-charged liquid, rich in all the properties from the herbs, fruits and raw materials that were subjected in this part of the production process .
- 5. The resulting liquid that comes out of the mixer now goes to another piece of equipment called a pressure filter. It is in this equipment that even the smallest solid particle that may be mixed with the liquid extract is separated. The objective in this part of the process is to obtain a liquid free of solid particles. In this stage we will take the opportunity to add those pending products that we did not add in the previous stage due to the high temperatures, these are the non-hydrolyzed collagen, the preservative, the lidocaine and the ascorbic acid.
- 6. The container chosen to store the final product is the container: Glass Ampoule for Injectable Solutions.
- 7. These containers are subjected to an automatic washing process in a machine that provides a pressurized water jet, this water is totally purified.
- 8. Once these containers leave the washing process, they enter a sterilization machine or dryer that will be in charge of sterilizing and drying the containers through the action of high temperatures.
- 9. Upon leaving the sterilization or drying machine, these containers enter an SCT Pharma oven, where the depyrogenation process will be carried out, which is nothing more than the process that will allow us to reduce the total or almost total endotoxins. Bacterial (Pyrogens), in other words what we are looking for is to obtain blisters free of all microorganisms and undesirable pathogenic substances, we achieve this through processes that use high temperatures, such as those that have been previously exposed.
- 10. The resulting solution that we obtained in step 5, coming from the filter, will now pass to a piece of equipment called the Vial Filling and Sealing Machine. The objective in this step is to dose the filtered solution as quickly as possible into the glass ampoules, taking care always not to wet the neck of the blisters. This stage will end with the injection of inert gas. This machine will later be in charge of sealing the valves, since it has a sealing system for glass-type ampoules, which were the types of packaging chosen in our process.
- 11. Once we have the glass ampoules ready, containing the product inside and duly sealed, they are sterilized, this with the aim of eliminating any possible microorganism or contamination that may have remained on the outside of the container during the process, for which uses a sterilization equipment called an autoclave, the process that is carried out in this equipment is sterilization by moist heat, in which this equipment uses saturated water vapor, at a pressure of 15 pounds, which allows the chamber to reach a temperature of 121°C, in this equipment the ampoules will last about 15 minutes going through the sterilization process.
- 12. The next stage is the stage called labeling, stage in which the label is placed on the product including basic information such as: batch number, dose, route of administration, manufacturing date, expiration date. The ampoules of injectable solution thus obtained. The next stage is the stage called labeling, stage in which the label is placed on the product including basic information such as: Lot number, Dosage, Manufacturing Date, Expiration Date, etc.
- The ampoules of injectable solution thus obtained according to the described process have an ambient storage stability of 2 years.
- Patients positive for coronavirus will undergo treatment for a period of 7 days with a dosage of 3 ampoules of intramuscular injectable solution per day. with a composition of ingredients per ampoule of:
Properly treated water 18.5% Non-hydrolyzed collagen 24% Dandelion 13% Anamu 18% Epazote 8% Oregano 8% Star anise 8.51% Lidocaine 1.8% anesthetic Benzoic Acid 0.17% preservative Ascorbic acid 0.02% antioxidant - A group of 5 patients was taken and they were evaluated through a self-assessment of their condition before starting the plan and after 7 days of treatment with two cups of tea a day, for this assessment they were asked to rate 1 On the 5th, his improvement with respect to his situation at the beginning of the treatment, the parameters to be assessed were muscle pain, dry cough, shortness of breath, diarrhea, tiredness, loss of the sense of smell and taste, body rash and fever. The following table shows the results of the self-assessment of their improvement with the tea treatment.
Table No. 1 Tabulation of the self-assessment of a sample of 5 patients in the improvement of their individual coronavirus status with treatment for 7 days with the tea object of the present invention, assessment of the improvement with a weighting from 1 to 5. Patient Headaches and muscle aches Cough and shortness of breath Loss of smell and taste Diarrhea and fever Before Assessment Before Assessment Before Assessment Before Assessment 1 Yes 5 Yes 5 Yes 5 Yes 5 2 Yes 5 Yes 5 Yes 5 Yes 5 3 Yes 4 Yes 5 Yes 4 Yes 5 4 Yes 5 Yes 5 no 0 Yes 5 5 Yes 5 Yes 5 Yes 4 Yes 5 Average rating improvement 4.80 5 4.50 5 - The results obtained from the self-assessment that each patient who underwent the tea treatment where no other medication was taken for the relief of covid-19.
- To be sure of its effectiveness, I was infected four times and the four times taking the formulation the symptoms disappeared with a proven improvement in 24 hours, the action of the formulation is one hundred percent effective, and does not carry any risk for the patient, with the advantage that it can be taken as prevention before being in places where there are people together without side effects, say an airplane; a restaurant; a cinema; since the virus would be inhibited by ingesting it. In 7 days, the person is recovered and it is a clear sign that the mechanism of action of these active ingredients disables the virus. Negative collateral reactions were manifested in none of the patients who received the treatment.
- We are facing a simple but great solution to this pandemic, soap is the only thing that inhibits it, and drinking it is the only solution.
Claims (11)
- Pharmaceutical composition for the treatment and prevention of coronavirus whose formulation contains as ingredients non-hydrolyzed collagen as a surfactant with degreasing properties together with natural active ingredients in the form of lyophilized powders of aqueous extracts characterized in that it comprises Dandelion (Taraxacum officinale), Anamú (Petiveria Alliacea), Epazote (Dysphania ambrosioides), Oregano (Origanum vulgare), star anise (Lllicium verun), together with preservatives.
- The composition of claim 1, characterized by the following list of ingredients:
Non-hydrolyzed collagen 1% up to 35% Dandelion extract 5% up to 30% Anamu extract 3% up to 20% Epazote extract 3% up to 20% Oregano extract 5% up to 25% Star anise extract 1% up to 15% Sodium benzoate 0.25% Potassium sorbate 0.25% - The composition of claim 1 which for oral administration is formulated in a hard gelatin capsule comprising:
Non-hydrolyzed collagen 25% Dandelion extract 20% Anamu extract 10% Epazote extract 15% Oregano extract 19.5% Star anise extract 10% Sodium benzoate 0.25% Potassium sorbate 0.25% - The composition of claim 1 that for its administration in the form of tea or infusion is formulated in a bag or sack of porous paper, silk or nylon to be dissolved in a rate of hot water comprising:
Non-hydrolyzed collagen 30% dandelion extract 15% anamu extract 15% Epazote extract 17% Oregano extract 15% Star anise extract 7.50% Sodium benzoate 0.25% Potassium sorbate 0.25% - The composition of claim 1 that for oral administration is formulated in drinkable ampoules, comprising:
Properly treated water 19.5% Non-hydrolyzed collagen 35% Dandelion Extract 10% Anamu Extract 8% Epazote Extract 12% Oregano extract 10% Star anise extract 5% Sodium benzoate 0.25% Potassium sorbate 0.25% - The composition of claim 1 for its administration is formulated in an intramuscular injectable solution, comprising:
Properly treated water 18.5% Non-hydrolyzed collagen 24% Dandelion extract 13% Anamu Extract 18% Epazote Extract 8% Oregano extract 8% Star anise extract 8.51% Lidocaine 1.8% anesthetic Benzoic Acid 0.17% Ascorbic acid 0.02% - Procedure for obtaining the active ingredients of the products characterized by the following steps:I. Inspection, classification, and approval of the raw material.II. Separation of shell and seeds to those raw materials that require it.III. Mixing of the raw materials with temperature control at 96°C (205°F), and stirring every 5 minutes.IV. Filtering and addition of preservatives.V. Homogenized spraying of the active ingredients and preservatives.VI. Preparation of the pharmaceutical form that is selected from: capsule, tea, drinkable ampoules or intramuscular injectable solution.
- The use of a composition according to claim 3 for the manufacture of a medicament for oral administration in the form of capsules characterized for the treatment and prevention of coronavirus.
- The use of a composition according to claim 4 for the manufacture of a medicament for oral administration in the form of tea or infusion for the treatment and prevention of coronavirus.
- The use of a composition according to claim 5 for the manufacture of a medicament for oral administration in the form of drinkable ampoules for the treatment and prevention of coronavirus.
- The use of a composition according to claim 6 for the manufacture of a medicament for intramuscular administration for the treatment and prevention of coronavirus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23211263.1A EP4299132A3 (en) | 2020-08-29 | 2020-08-29 | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2020/058079 WO2022043738A1 (en) | 2020-08-29 | 2020-08-29 | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23211263.1A Division EP4299132A3 (en) | 2020-08-29 | 2020-08-29 | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
EP23211263.1A Division-Into EP4299132A3 (en) | 2020-08-29 | 2020-08-29 | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
Publications (4)
Publication Number | Publication Date |
---|---|
EP4104851A1 true EP4104851A1 (en) | 2022-12-21 |
EP4104851A4 EP4104851A4 (en) | 2023-03-01 |
EP4104851C0 EP4104851C0 (en) | 2023-12-27 |
EP4104851B1 EP4104851B1 (en) | 2023-12-27 |
Family
ID=80354728
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23211263.1A Pending EP4299132A3 (en) | 2020-08-29 | 2020-08-29 | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
EP20951308.4A Active EP4104851B1 (en) | 2020-08-29 | 2020-08-29 | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23211263.1A Pending EP4299132A3 (en) | 2020-08-29 | 2020-08-29 | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230057094A1 (en) |
EP (2) | EP4299132A3 (en) |
CO (1) | CO2022010604A2 (en) |
CR (1) | CR20220414A (en) |
DO (1) | DOP2022000178A (en) |
EC (1) | ECSP22066025A (en) |
ES (1) | ES2975224T3 (en) |
MX (1) | MX2022009370A (en) |
PE (1) | PE20231359A1 (en) |
WO (1) | WO2022043738A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037296A1 (en) | 2003-10-16 | 2005-04-28 | Toagosei Co., Ltd. | Anti-coronavirus agent |
CA2569080A1 (en) | 2006-11-20 | 2008-05-20 | Institut Pasteur | Anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus |
CN105687226B (en) | 2016-01-27 | 2018-04-13 | 中国人民解放军疾病预防控制所 | A kind of preparation for being used to suppress coronavirus infection |
CN111281914A (en) * | 2020-02-16 | 2020-06-16 | 丁虹 | Traditional Chinese medicine composition for treating pneumonia |
CN111467414A (en) * | 2020-02-18 | 2020-07-31 | 上海蓝盎医学科技发展有限公司 | A Chinese medicinal composition for treating new coronavirus, and its preparation method |
CN111298049A (en) * | 2020-04-22 | 2020-06-19 | 南昌大学第一附属医院 | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof |
CN111407859A (en) * | 2020-04-29 | 2020-07-14 | 北京天然风尚健康科技有限公司 | Preparation method and application of armor essential oil composition with antibacterial and antiviral effects |
CN111569010B (en) * | 2020-05-06 | 2021-08-20 | 石家庄市第五医院 | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating neocoronary pneumonia |
CN111534877B (en) * | 2020-06-04 | 2021-01-15 | 广州市中诚新型材料科技有限公司 | Compound Chinese medicinal multifunctional antibacterial fiber for resisting coronavirus and influenza virus |
-
2020
- 2020-08-29 ES ES20951308T patent/ES2975224T3/en active Active
- 2020-08-29 CR CR20220414A patent/CR20220414A/en unknown
- 2020-08-29 PE PE2022001809A patent/PE20231359A1/en unknown
- 2020-08-29 EP EP23211263.1A patent/EP4299132A3/en active Pending
- 2020-08-29 EP EP20951308.4A patent/EP4104851B1/en active Active
- 2020-08-29 MX MX2022009370A patent/MX2022009370A/en unknown
- 2020-08-29 US US17/759,123 patent/US20230057094A1/en active Pending
- 2020-08-29 WO PCT/IB2020/058079 patent/WO2022043738A1/en unknown
-
2022
- 2022-07-28 CO CONC2022/0010604A patent/CO2022010604A2/en unknown
- 2022-08-23 EC ECSENADI202266025A patent/ECSP22066025A/en unknown
- 2022-09-05 DO DO2022000178A patent/DOP2022000178A/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20231359A1 (en) | 2023-09-05 |
EP4104851C0 (en) | 2023-12-27 |
CO2022010604A2 (en) | 2022-10-11 |
ES2975224T3 (en) | 2024-07-04 |
DOP2022000178A (en) | 2022-11-15 |
CR20220414A (en) | 2022-09-15 |
EP4299132A2 (en) | 2024-01-03 |
MX2022009370A (en) | 2022-09-02 |
EP4104851A4 (en) | 2023-03-01 |
US20230057094A1 (en) | 2023-02-23 |
EP4299132A3 (en) | 2024-02-21 |
EP4104851B1 (en) | 2023-12-27 |
ECSP22066025A (en) | 2022-09-30 |
WO2022043738A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106668832B (en) | Application of polypeptide in preparation of medicine for treating enterovirus infection | |
AU2018349244B2 (en) | N-acetylneuraminic acid compositions and methods of use | |
RU2568582C1 (en) | Method for non-specific immunoprophylaxis of bovine respiratory diseases | |
CN103142948A (en) | Medicine for preventing and treating respiratory diseases, and its preparation method | |
CN102319288B (en) | Pure traditional Chinese medicine composition for treating poultry infectious bursal disease and preparation method thereof | |
EP4104851B1 (en) | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus | |
KR20220161413A (en) | Sialic acid compositions for use in inhibiting and treating coronavirus infections | |
Saaty | Grapefruit seed extracts’ antibacterial and antiviral activity: Anti-severe acute respiratory syndrome coronavirus 2 impact | |
CN110327423A (en) | A kind of anti-inflammatory spray of the department of stomatology containing bletilla striata extract ingredient and larynx section | |
CN101328457A (en) | Antibiotic antivirus perfumed soap containing oil of aromatic turmeric ingredient | |
KR102252009B1 (en) | Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf | |
CN107913234A (en) | A kind of savatier monochasma herb toothpaste and preparation method thereof | |
CN111450298A (en) | Marine brown algae oligosaccharide herbal atomizing agent and preparation method thereof | |
WO2021212269A1 (en) | Application of ellagic acid in preventing and treating novel coronavirus infection | |
CN106344453A (en) | Novel acne cream and preparation method thereof | |
CN112402500A (en) | Application of traditional Chinese medicine preparation in preventing and killing coronavirus | |
CN113350487A (en) | Antiviral composition and preparation method and application thereof | |
CN109498735A (en) | Medicine for treating mosquito bites and preparation method thereof | |
US20230102810A1 (en) | The use of unripened green mangifera indica as a natural preparation to treat sars-cov-2 | |
CN103356698B (en) | Composite mineral active-state bath agent | |
WO2017110767A1 (en) | Anti-norovirus composition and utilization thereof | |
US20230285487A1 (en) | Pharmaceutical composition based on plant extracts for the treatment of fibromyalgia, rheumatoid arthritis, lupus and other autoimmune diseases | |
US11564967B1 (en) | Oral compositions containing extracts of a betel leaf and related methods | |
CN106362017A (en) | Traditional Chinese medicine disinfectant and preparation method thereof | |
CN115089634A (en) | Bezoar/essential oil composition for preventing and treating new coronary pneumonia, preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220912 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230201 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/12 20060101ALI20230126BHEP Ipc: A61K 9/08 20060101ALI20230126BHEP Ipc: A61K 9/14 20060101ALI20230126BHEP Ipc: A61K 9/48 20060101ALI20230126BHEP Ipc: A61K 36/36 20060101ALI20230126BHEP Ipc: A61K 36/79 20060101ALI20230126BHEP Ipc: A61K 36/53 20060101ALI20230126BHEP Ipc: A61K 36/22 20060101ALI20230126BHEP Ipc: A61K 36/288 20060101ALI20230126BHEP Ipc: A61K 38/39 20060101AFI20230126BHEP |
|
17Q | First examination report despatched |
Effective date: 20230213 |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTG | Intention to grant announced |
Effective date: 20231031 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020023631 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20240111 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240328 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240328 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240327 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240427 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2975224 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240704 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240427 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231227 |
|
U20 | Renewal fee paid [unitary effect] |
Year of fee payment: 5 Effective date: 20240902 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240815 Year of fee payment: 5 |